

Market Announcement

12 October 2021

Recce Pharmaceuticals Ltd (ASX: RCE) – Suspension from Quotation

Description

The securities of Recce Pharmaceuticals Ltd ('RCE') will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement regarding an application to the Supreme Court of New South Wales.

Issued by

Belinda Giles

Adviser, Listings Compliance (Perth)

ASX Announcement

12 October 2021

Oma Murad
Adviser Listings Compliance (Perth)
Level 40 Central Park
152-158 St George's Terrace
Perth WA 6000

By email: tradinghaltsperth@asx.com.au

Dear Oma,

Recce Pharmaceuticals Ltd (ASX:RCE) – Voluntary Suspension request

Pursuant to ASX Listing Rule 17.2, Recce Pharmaceuticals Ltd (ASX: RCE) (**Company**) requests for a voluntary suspension of its securities from prior to commencement of trading today.

The Company provides the following information for the purposes of ASX Listing Rule 17.2:

1. The Company requests the voluntary suspension pending the outcome of the application to the Supreme Court of New South Wales referred to in its request for trading halt and ASX announcement dated 8 October 2012.
2. The Company requests that the voluntary suspension continue until the Company releases an announcement in relation to the outcome of the Court application, which is expected to be 13 October 2021.
3. The Company is not aware of any reason why the voluntary suspension should not be granted.
4. The Company is not aware of any other information necessary to inform the market about the voluntary suspension.

This request has been authorised by the Board of Directors.

For any questions, please contact the undersigned on +61 2 8072 1400.

Yours faithfully



Alistair McKeough
Company Secretary



ASX: RCE

Head Office: Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 T +61 (02) 9256 2571

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA